(RTTNews) - Evaxion Biotech (EVAX) reported clinical phase 2 data for its lead compound EVX-01. The data showed that 11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate. 15 out of the 16 patients had reduction of their tumors.
The topline data is part of a one-year interim analysis of the ongoing phase 2 trial assessing EVX-01 in combination with MSD's anti-PD-1 therapy, KEYTRUDA in patients with advanced melanoma. The complete one-year dataset will be presented at the ESMO congress this week.
"We look forward to presenting the complete one-year dataset at ESMO, discussing the data with potential partners and advancing the phase 2 trial towards its completion next year," said Christian Kanstrup, CEO of Evaxion.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
